What the trial was testing
The trial enrolled 50 patients with multiple myeloma. The study was sponsored by Millennium Pharmaceuticals and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was an early-stage trial — researchers are still confirming safety and getting an early look at how well the treatment works. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
47% tumor response rate — and responses lasted nearly 2 years.
Blood Neoplasia · 2024 · NCT03439280
These findings — that rate at 600 mg mezagitamab in heavily pretreated relapsed multiple myeloma — were published in the Blood Neoplasia and represent the headline result of the study.
Researchers tracked outcomes across 50 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with multiple myeloma, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Mezagitamab is still in development and not yet FDA-approved for multiple myeloma. Daratumumab (Darzalex) and isatuximab (Sarclisa) — two other anti-CD38 antibodies — are FDA-approved and available now for myeloma. The drug company has decided not to pursue further myeloma development. Ask a hematologist about approved CD38 options.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open multiple myeloma trials
Elranatamab in R/R Multiple Myeloma
This research is being done to see if the study drug, elranatamab, reduces the risk of disease progression (worsening disease) after idecabtagene vicleucel in relapsed refractory multiple myeloma.
DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
Evaluate the efficacy of DVRd in patients with newly diagnosed double-hit multiple myeloma (MM) and the feasibility of minimal residual disease (MRD) guided maintenance therapy